{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/heart-failure-chronic/prescribing-information/managing-beta-blockers/","result":{"pageContext":{"chapter":{"id":"df53e9a8-07f8-5d37-94cf-78e99d4c8216","slug":"managing-beta-blockers","fullItemName":"Managing beta-blockers","depth":2,"htmlHeader":"<!-- begin field dbbe1ba6-96c8-43ca-acba-546ab73a2c4a --><h2>Beta-blockers</h2><!-- end field dbbe1ba6-96c8-43ca-acba-546ab73a2c4a -->","summary":"","htmlStringContent":"<!-- begin item 4ddf56c4-95a0-4e7c-a333-90f0c6390dd3 --><!-- end item 4ddf56c4-95a0-4e7c-a333-90f0c6390dd3 -->","topic":{"id":"3a35207f-30ea-5eca-bfcf-dff091a73359","topicId":"fdc42e20-2c4b-45ed-9093-6c2d4bde6e4d","topicName":"Heart failure - chronic","slug":"heart-failure-chronic","lastRevised":"Last revised in January 2017","chapters":[{"id":"77c928c1-46d0-58c1-ba79-6015f89bc48a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f0aa9151-9d10-566e-85ec-6ccefed25f20","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c036596d-f29d-5486-822a-b46af76451d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd5e8a95-3e97-5ec2-98ae-5a10c2373213","slug":"changes","fullItemName":"Changes"},{"id":"4c4375f1-a348-5b99-b895-f04a15c64791","slug":"update","fullItemName":"Update"}]},{"id":"7472c037-35d4-5fd2-bba6-dfd891ade816","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cde936d1-3945-5bc6-8c22-9106d78cf77c","slug":"goals","fullItemName":"Goals"},{"id":"bfa0b8d3-fac0-500e-a762-f719dc619f1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5d2cf55e-1ae2-5000-9c94-e9c86d26a824","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c8203a8a-fc22-5378-b33b-34ddf818dea5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4b5e4f72-1a3e-531c-be82-a1919603c934","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c206f1b2-7616-587d-b3bf-b65ba5b5adb4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ab1d2b81-1f2b-55e5-abf0-c14e4ae4a78d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"cb83ac3c-e97e-5cab-acca-5abebc7bd6b1","slug":"definition","fullItemName":"Definition"},{"id":"66c995b7-504c-5510-9e77-1a9b27ee7dca","slug":"causes","fullItemName":"Causes"},{"id":"88dbdf7b-53b7-5952-97b9-2312c0a2ce63","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0b16521-d808-5dfd-89dc-64fc6ae7f6ce","slug":"prognosis","fullItemName":"Prognosis"},{"id":"262fb896-526d-594f-8142-98c291781249","slug":"complications","fullItemName":"Complications"}]},{"id":"72804751-fb0c-5a96-85b5-982feb950f16","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8b798e41-3fbe-5027-9365-da41e1c98e93","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"e6498250-f313-5ea2-a1e8-2d0342823c39","slug":"how-to-manage-suspected","fullItemName":"How to manage suspected"},{"id":"74e553b4-7cb8-52a6-a573-8715f63a2ba8","slug":"how-to-assess","fullItemName":"How to assess"},{"id":"53bf7ae0-a1d0-5fae-9d3b-57cbc6f03bb8","slug":"what-else-could-it-be","fullItemName":"What else could it be"}]},{"id":"38c5edc8-6b4a-5e71-bb70-cf0a09389ae0","fullItemName":"Management","slug":"management","subChapters":[{"id":"97a0eca4-a290-588b-a16a-bc95b93cd893","slug":"confirmed-heart-failure-with-reduced-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with reduced ejection fraction"},{"id":"34ff8094-815a-55b7-9edd-49f3ac636471","slug":"confirmed-heart-failure-with-preserved-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with preserved ejection fraction"},{"id":"28fde475-ef24-59d3-9171-a8d59a3fb149","slug":"end-stage-heart-failure","fullItemName":"Scenario: End-stage heart failure"},{"id":"c587255a-a47e-57a1-bc4d-967753c38d11","slug":"information-advice-follow-up-referral","fullItemName":"Scenario: Information and advice, follow-up, and referral"}]},{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8fd96acc-3fa6-528b-9351-49db836228b1","slug":"managing-aiiras","fullItemName":"Managing AIIRAs"},{"id":"06c9d276-e5ea-5a0b-9ff4-343f10034763","slug":"managing-ace-inhibitors","fullItemName":"Managing ACE-inhibitors"},{"id":"df53e9a8-07f8-5d37-94cf-78e99d4c8216","slug":"managing-beta-blockers","fullItemName":"Managing beta-blockers"},{"id":"faad170c-d1ee-59ad-9847-f7afdda6d9b9","slug":"managing-diuretics","fullItemName":"Managing diuretics"},{"id":"a3ea6beb-7ee3-586c-9985-47c20d804195","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"7b9c5d56-39f1-53df-b1f9-2dcc5bbb498a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"df3b6e0c-ca5a-59eb-93e6-4b4370389ed2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7a756ff1-7152-5bdd-92ca-7f9e67351dd9","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f5e1707e-f2a9-54e0-92fa-71beb41e38af","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"691681cc-720f-5242-9fb3-3040860027e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7f39ec24-cb87-5fba-ae6b-6fb2d9538859","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4afe2b30-f837-53a3-88df-7b1913a54081","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d4dace55-ef1c-5675-bdbe-180512d549fa","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"25516d03-e379-5688-9253-054cdbaa6409","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e56ad25b-c1cd-4688-aa0e-da3a2138832b --><h3>Contraindications and cautions of beta-blockers</h3><!-- end field e56ad25b-c1cd-4688-aa0e-da3a2138832b -->","summary":"","htmlStringContent":"<!-- begin item 4a2fca19-741a-4443-9a0b-0ee97e89b3f2 --><!-- begin field d6208211-6e57-435f-b1e2-9e84bca1cd06 --><ul><li><strong>Do not prescribe beta-blockers to people with:</strong><ul><li>A history of asthma or bronchospasm.</li><li>Reversible or severe chronic obstructive pulmonary disease (COPD). Beta-blockers can be used in people with COPD without significant reversible airways obstruction.</li><li>Known intolerance or hypersensitivity to beta-blockers.</li><li>Severe or symptomatic bradycardia (heart rate less than 60 beats per minute).</li><li>Sinoatrial block, second- or third-degree heart block (unless there is a pacemaker in place).</li><li>Severe or uncontrolled heart failure.</li><li>Severe or symptomatic hypotension (systolic blood pressure less than 90 mmHg).</li><li>Severe peripheral arterial disease (including intermittent claudication) or Raynaud's syndrome.</li><li>Sick sinus syndrome.</li><li>Cardiogenic shock or phaeochromocytoma (without a concomitant alpha-blocker).</li><li>Prinzmetal's angina.</li><li>People with frequent episodes of hypoglycaemia.</li><li>Clinically significant hepatic dysfunction (carvedilol and nebivolol).</li><li>Some beta-blocker preparations contain lactulose and should not be used by people with rare hereditary problems of galactose intolerance, fructose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.</li></ul></li><li><strong>Prescribe beta-blockers with caution to people with:</strong><ul><li>Heart failure with chronic kidney disease (CKD), hypotension, ischaemic heart disease, or less severe peripheral arterial disease.</li><li>Current or recent (within 4 weeks) exacerbation of heart failure — seek specialist advice.</li><li>First-degree atrioventricular heart block.</li><li>Portal hypertension (risk of deterioration in liver function).</li><li>Diabetes mellitus (effects carbohydrate metabolism and symptoms of hypoglycaemia may be masked).</li><li>COPD.</li><li>Strict fasting.</li><li>Mysthenia gravis.</li><li>Psoriasis.</li><li>Thyrotoxicosis (symptoms may be masked).</li><li>People who wear contact lenses (reduced secretion of lacrimal fluid).</li><li>History of hypersensitivity to allergens — beta-blockers may increase sensitivity to allergens and result in a more serious hypersensitivity response, and may reduce response to adrenaline (epinephrine).</li><li>CKD.</li></ul></li><li><strong>Consider the possibilities of <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-beta-blockers/#key-drug-interactions\">drug interactions</a> with other medications.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guideline Centre for Acute and Chronic Conditions, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field d6208211-6e57-435f-b1e2-9e84bca1cd06 --><!-- end item 4a2fca19-741a-4443-9a0b-0ee97e89b3f2 -->","subChapters":[]},{"id":"e907dc44-a4eb-5b18-acc2-6487e8a86d34","slug":"choice-of-beta-blocker","fullItemName":"Choice of beta-blocker","depth":3,"htmlHeader":"<!-- begin field 4ce876bf-52e0-4a91-ab53-dd44d69bf0e0 --><h3>Choice of beta-blocker</h3><!-- end field 4ce876bf-52e0-4a91-ab53-dd44d69bf0e0 -->","summary":"","htmlStringContent":"<!-- begin item 754ed02e-3b2d-4234-93e8-45eb63f0dbf9 --><!-- begin field 199f7b72-2ef9-4808-98f0-625eec2e3758 --><ul><li><strong>The beta-blockers licensed in the UK for the treatment of heart failure are bisoprolol, carvedilol, and nebivolol.</strong><ul><li>Nebivolol is licensed for stable mild to moderate heart failure in people aged 70 years or older.</li><li>People with stable symptoms who are receiving treatment with a beta-blocker for a concomitant condition (for example angina or hypertension) who develop heart failure with reduced ejection fraction (HF-REF) should switch their current beta-blocker to a beta-blocker licensed for treating heart failure.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guideline Centre for Acute and Chronic Conditions, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 199f7b72-2ef9-4808-98f0-625eec2e3758 --><!-- end item 754ed02e-3b2d-4234-93e8-45eb63f0dbf9 -->","subChapters":[]},{"id":"e35c3ea5-dd67-5f5e-9365-26a2e2127623","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 879e24dd-5329-46bc-bf70-2b5af4ec8853 --><h3>Adverse effects of beta-blockers</h3><!-- end field 879e24dd-5329-46bc-bf70-2b5af4ec8853 -->","summary":"","htmlStringContent":"<!-- begin item 6b9a3b11-5d48-4065-915e-be24b736a1ae --><!-- begin field 995bd51b-681b-4875-b02f-da9ec9c8e63e --><ul><li><strong>Adverse effects of beta-blockers which require monitoring include:</strong><ul><li>Deteriorating symptoms of heart failure (such as symptoms of fluid overload and fatigue).</li><li>Hypotension.</li><li>Bradycardia.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Dizziness, headache, and syncope.</li><li>Nausea, vomiting, diarrhoea, and constipation.</li><li>Sexual dysfunction — including erectile dysfunction and loss of libido.</li><li>Cold extremities, paraesthesiae, and numbness — these are more common in people with peripheral arterial disease. If these are troublesome, the beta-blocker may need to be stopped.</li><li>Effect on carbohydrate metabolism — hypo- or hyperglycaemia in people with or without diabetes mellitus.</li><li>Effect on metabolic and autonomic response to hypoglycaemia — possible masking of hypoglycaemia warning signs such as tremor and tachycardia.</li><li>Fatigue and asthenia (lack of energy and strength) — is a common adverse effect of bisoprolol.</li><li>Sleep disturbance, nightmares, and depression.</li><li>Bronchospasm — bisoprolol and nebivolol are relatively cardioselective (but not cardiospecific) so may have less effect on airways resistance than carvedilol.</li><li>Reduction of secretion of lacrimal fluid (may affect people who wear contact lenses).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 995bd51b-681b-4875-b02f-da9ec9c8e63e --><!-- end item 6b9a3b11-5d48-4065-915e-be24b736a1ae -->","subChapters":[]},{"id":"12e6692a-ce4c-5744-bb94-9cd56d42df7e","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 3fdb4618-6ecc-4ba0-b436-7d8b73eb238c --><h3>Dose and titration of beta-blockers</h3><!-- end field 3fdb4618-6ecc-4ba0-b436-7d8b73eb238c -->","summary":"","htmlStringContent":"<!-- begin item 5810b17e-015b-4291-b56a-c22cd18580f1 --><!-- begin field 3783be02-ce2f-433c-ad8f-f93c7e9df9f0 --><ul><li><strong>A beta-blocker should only be started once the person is stable (without fluid overload or hypotension).</strong></li><li><strong>Advise people:</strong><ul><li>That there may be an initial temporary worsening of symptoms during initiation or up-titration but that symptoms may improve slowly over 3–6 months.</li><li>To seek medical advice if they experience a worsening of symptoms such as tiredness, fatigue, weight gain, or breathlessness. For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">Self-care advice</a>.</li><li>Not to stop beta-blockers without consulting a healthcare professional.</li></ul></li><li><strong>Start at a low dose and titrate slowly upwards until the target dose or the highest tolerated dose is reached. Starting and target doses are shown in Table 4.</strong><ul><li>Beta-blockers should not be stopped suddenly unless this is absolutely necessary; there is a risk of rebound myocardial ischaemia or infarction, or arrhythmias. Ideally, specialist advice should be sought before stopping a beta-blocker.</li><li>If symptoms of chronic obstructive airways disease (COPD) worsen, a reduction in dose, or withdrawal, may be necessary.</li></ul></li><li><strong>Monitor heart rate, blood pressure, and clinical status (for symptoms and signs of heart failure) after each dose increase.</strong> Do not increase the dose if the person has signs of worsening heart failure, symptomatic hypotension (such as dizziness), or excessive bradycardia (heart rate less than 50 beats per minute).<ul><li><strong>If the heart rate decreases to 50 beats per minute or less, consider:</strong><ul><li>Halving the dose of beta-blocker or if there is a severe clinical deterioration consider stopping the beta-blocker (seek specialist advice).</li><li>Reviewing the need for other drugs that slow heart rate (for example digoxin, amiodarone, diltiazem, or verapamil).</li><li>Arranging for an ECG to exclude heart block.</li><li>Seeking specialist advice.</li></ul></li><li><strong>If the blood pressure is low:</strong><ul><li>Asymptomatic low blood pressure may not require a change in therapy.</li><li>If symptomatic, consider stopping nitrates, calcium-channel blockers, or other vasodilators if dizziness, light headedness, or confusion is present. Consider reducing the diuretic dose if the person does not have signs of fluid overload. Seek specialist advice if symptoms persist.</li></ul></li><li><strong>If the clinical status is worsening</strong> (for example increasing dyspnoea, fatigue, oedema, or weight gain), consider the following options:<ul><li>For increased fluid overload — increase the dose of diuretic and if this does not work, consider halving the dose of beta-blocker.</li><li>For marked fatigue — halve the dose of beta-blocker, review the person in 1–2 weeks, and seek specialist advice.</li><li>For serious deterioration — halve the dose or stop the beta-blocker and seek specialist advice.</li><li>Review the person in 1–2 weeks and if there is no improvement, seek specialist advice.</li></ul></li></ul></li><li><strong>Continue treatment at the target dose or highest tolerated dose indefinitely unless complications occur.</strong></li></ul><p><strong>Table 4. </strong>Doses of beta-blockers recommended for heart failure.</p><table data-table-id=\"385559c9-13ee-49fa-8a3c-acce014fcf03\"><thead><tr><th colspan=\"1\" scope=\"col\">Beta-blocker</th><th colspan=\"1\" scope=\"col\">Initial dose</th><th colspan=\"1\" scope=\"col\">Target dose</th><th colspan=\"1\" scope=\"col\">Titration regimen</th></tr></thead><tbody><tr><td colspan=\"1\">Bisoprolol</td><td colspan=\"1\">1.25 mg once a day †</td><td colspan=\"1\">10 mg once a day</td><td colspan=\"1\">Increase from 1.25 mg to 2.5 mg to 3.75 mg to 5 mg at 1-week intervals. After taking 5 mg once a day for 4 weeks, increase to 7.5 mg and after another 4 weeks, increase to 10 mg.</td></tr><tr><td colspan=\"1\">Carvedilol</td><td colspan=\"1\">3.125 mg twice a day †</td><td colspan=\"1\">25–50 mg twice a day</td><td colspan=\"1\">Titrate the dose by doubling every 2 weeks. If the person has severe heart failure or weighs less than 85 kg, the target dose is 25 mg twice a day. If the person has mild to moderate heart failure and weighs more than 85 kg, the target dose is 50 mg twice a day.</td></tr><tr><td colspan=\"1\">Nebivolol †‡</td><td colspan=\"1\">1.25 mg once a day</td><td colspan=\"1\">10 mg once a day</td><td colspan=\"1\">Increase dose from 1.25 mg to 2.5 mg to 5 mg, and finally to 10 mg, leaving an interval of 1–2 weeks between dose increases, depending on the person's ability to tolerate the drug.</td></tr><tr><td colspan=\"4\">† With food ‡ Licensed for heart failure in people aged over 70 years</td></tr><tr><td colspan=\"4\"><p><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015h</a>]</p></td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guideline Centre for Acute and Chronic Conditions, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 3783be02-ce2f-433c-ad8f-f93c7e9df9f0 --><!-- end item 5810b17e-015b-4291-b56a-c22cd18580f1 -->","subChapters":[]},{"id":"2918f6a1-9b7d-5151-a9c9-20a5d53a16e4","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 47f844d1-c0db-4a10-a037-daa8a6e6f5ab --><h3>Beta-blockers in pregnancy and breastfeeding</h3><!-- end field 47f844d1-c0db-4a10-a037-daa8a6e6f5ab -->","summary":"","htmlStringContent":"<!-- begin item b350e032-e499-4502-aebb-c43fdb4af723 --><!-- begin field 341459ce-8a3d-40b9-9ec3-95cbda77c6ab --><h4>Pregnancy</h4><ul><li>Bisoprolol and carvedilol have effects which may cause harm to the pregnancy including reduced placental perfusion which may cause growth retardation, intrauterine death, miscarriage, or early labour.</li><li>Adverse effects on the fetus or newborn include hypoglycaemia, bradycardia, respiratory depression and hypothermia.</li><li>Bisoprolol and carvedilol are not recommended during pregnancy unless clearly necessary. If prescribed, carvedilol treatment should be stopped 2-3 days before the expected birth if possible.</li><li>If beta-blockers are prescribed, placental blood flow, fetal growth and the newborn infant should be closely monitored.</li></ul><h4>Breastfeeding</h4><ul><li>Bisoprolol and carvedilol are not recommended for use by women who are breastfeeding.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 341459ce-8a3d-40b9-9ec3-95cbda77c6ab --><!-- end item b350e032-e499-4502-aebb-c43fdb4af723 -->","subChapters":[]},{"id":"29502d2d-821c-5ac9-81e8-caf12f7da7a4","slug":"key-drug-interactions","fullItemName":"Key drug interactions","depth":3,"htmlHeader":"<!-- begin field 68fe2d5e-060e-4d8a-a744-c9e8d8f3a090 --><h3>Key drug interactions with beta-blockers</h3><!-- end field 68fe2d5e-060e-4d8a-a744-c9e8d8f3a090 -->","summary":"","htmlStringContent":"<!-- begin item efe7bb5f-40a7-4ff3-9a2a-c681f863b303 --><!-- begin field 5fd34ab1-2511-4c9d-b969-8e366c2af20b --><p><strong>Important drug interactions of beta-blockers include:</strong></p><ul><li><strong>Antipsychotics and antidepressants</strong> (tricyclic, barbiturates, and phenothiazines) — risk of hypotension.</li><li><strong>Baclofen</strong> — prescribe with caution due to increased hypotensive effect.</li><li>Dihydropyridine calcium-channel blockers (including amlodipine, felodipine, and nifedipine) — risk of increased hypotension and worsening heart failure.</li><li><strong>Verapamil</strong> — concurrent beta-blocker and verapamil should not be prescribed because of the risk of bradycardia, asystole, severe hypotension, and heart failure.</li><li><strong>Diltiazem</strong> — obtain specialist advice before prescribing diltiazem with a beta-blocker.<ul><li>Heart rate and blood pressure should be monitored carefully, as bradycardia and atrioventricular (AV) block can occur. Asystole and sudden death have been reported.</li></ul></li><li><strong>Class I antiarrhythmics</strong> (such as quinidine, flecainide) — concurrent treatment should be avoided due to bradycardia, myocardial depression and potentiation of AV conduction time.</li><li><strong>Class III antiarrhythmics</strong> (such as amiodarone) — concurrent treatment should be prescribed with caution.<ul><li>Monitor heart rate and blood pressure and check for signs of worsening heart failure, as risk of bradycardia, AV block, and myocardial depression is increased.</li></ul></li><li><strong>Digoxin</strong> — concurrent treatment can reduce heart rate and prolong AV conduction time, increasing the risk of AV block and bradycardia.<ul><li>Monitor pulse carefully.</li><li>Monitor for signs of digoxin toxicity with carvedilol (confusion, anorexia, nausea, disturbance of colour vision) as an increase in plasma digoxin levels has been reported with carvedilol.</li></ul></li><li><strong>Insulin and oral antidiabetic drugs</strong> — prescribe with caution due to masking of symptoms of hypoglycaemia.</li><li><strong>Sympathomimetic agents</strong> — risk of hypertension, severe bradycardia, and heart block.</li><li><strong>Any other drugs that reduce blood pressure</strong> (including nitrates) — risk of additive hypotensive effect, or worsening of heart failure.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 5fd34ab1-2511-4c9d-b969-8e366c2af20b --><!-- end item efe7bb5f-40a7-4ff3-9a2a-c681f863b303 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}